Senior Director Drug Discovery and Early
Tibotec
Senior Director Drug Discovery and Early Development, Infectious Diseases and Vaccines
Wyeth Collegeville Pa 2005 - 2008
Research Fellow, Cardiovascular and Metabolic Diseases
Schering-Plough Research Institute 1997 - 2005
Senior Research Fellow, Anti-Infectives Division
Education:
University of California, Berkeley
Doctorates, Doctor of Philosophy, Biochemistry
Skills:
Drug Discovery Infectious Diseases Vaccines Metabolism Lifesciences Drug Development Biotechnology Clinical Development Pharmaceutical Industry Medicinal Chemistry Molecular Biology Virology Immunology Protein Chemistry Assay Development Elisa Drug Design High Throughput Screening In Vitro Cell Biochemistry Pharmacology In Vivo
Covalent HCV NS4A-NS3 complexes comprising the central hydrophobic domain of native HCV NS4A peptide, a linker, and the HCV NS3 serine protease domain, wherein the hydrophobic domain of native HCV NS4A peptide is tethered by the linker to the amino terminus of the HCV NS3 protease domain.
Diaryl Peptides As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Zhaoning Zhu - East Windsor NJ, US Srikanth Venkatraman - Woodbridge NJ, US F. George Njoroge - Warren NJ, US Ashok Arasappan - Bridgewater NJ, US Bruce A. Malcolm - Westfield NJ, US Viyyoor M. Girijavallabhan - Parsippany NJ, US Raymond G. Lovey - West Caldwell NJ, US Kevin X. Chen - Iselin NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K038/17 A61K031/33 C07K007/64
US Classification:
514 9, 530317, 540455, 514183
Abstract:
The present invention is directed to certain diaryl amide compounds as NS3-Serine protease inhibitors of hepatitis C virus. A particularly preferred compound is of the formula:.
Codon-Optimized Β-Secretase And Methods Of Refolding And Processing
Brian M. Beyer - Lincroft NJ, US Bruce A. Malcolm - Westfield NJ, US Corey O. Strickland - Martinsville NJ, US Wenyan Wang - Edison NJ, US Eileen Wilson - Raritan NJ, US
The present application relates to methods for growing crystals of both the uncomplexed and complexed forms of β-secretase (BACE) polypeptide. Polypeptides used herein are derived from human BACE which is also known by the synonyms “mamapsin 2”, “human β-site APP-cleaving enzyme, and Asp2”. The present application also relates to crystalline forms of uncomplexed BACE and the three-dimensional structure of BACE, as determined from the crystals. In addition, the present application relates to the use of crystalline forms of BACE to identify ligands, preferably inhibitors (antagonists), which bind to, and preferably inhibit the enzymatic activity of, BACE. Furthermore, the present application relates to nucleic acid sequences encoding BACE polypeptide, and methods for making BACE in greater quantity than prior methods, resulting in more effective crystallization.
Bruce A. Malcolm - Westfield NJ, US Robert Palermo - New York NY, US Xiao Tong - East Brunswick NJ, US Boris Feld - New Milford NJ, US Hung Le - Rockaway NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A01N 43/04 A61K 31/70
US Classification:
514 49, 514 42, 514 43, 514 52
Abstract:
The present invention provides methods for treating infections, in a host, by viruses belonging to the Flaviviridae family, such as HCV, comprising administering an Ara-C homologue to the host.
Method For Making Β-Secretase Co-Crystals Complexed With A Ligand
Brian M. Beyer - Lincroft NJ, US Bruce A. Malcolm - Paoli PA, US Corey O. Strickland - Martinsville NJ, US Wenyan Wang - Edison NJ, US Eileen Wilson - Raritan NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
G01N 31/00 G01N 33/00
US Classification:
436 4, 435183, 117927
Abstract:
The present application relates to methods for growing crystals of both the uncomplexed and complexed forms of β-secretase (BACE) polypeptide. The present application also relates to crystalline forms of uncomplexed BACE and the three-dimensional structure of BACE, as determined from the crystals. In addition, the present application relates to the use of crystalline forms of BACE to identify ligands, preferably inhibitors (antagonists), which bind to, and preferably inhibit the enzymatic activity of, BACE. Furthermore, the present application relates to nucleic acid sequences encoding human BACE polypeptide, and methods for making BACE in greater quantity than prior methods, resulting in more effective crystallization.
Pharmaceutical Formulations And Methods Of Treatment Using The Same
Bruce A. Malcolm - Paoli PA, US Prudence K. Bradley - Cranford NJ, US Anastasia Pavlovsky - Morris Plains NJ, US Wing-Kee Philip Cho - Princeton NJ, US Zhihui Qiu - Bridgewater NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K 38/12
US Classification:
514 2, 514 9, 514 16, 514 17, 514 18
Abstract:
Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.
Bruce A. Malcolm - Paoli PA, US Robert Palermo - Seattle WA, US Xiao Tong - Short Hills NJ, US Boris Feld - New Milford NJ, US Hung Le - Rockaway NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A01N 43/04 A61K 31/70
US Classification:
514 49, 514 42, 514 43, 514 52
Abstract:
The present invention provides methods for treating infections, in a host, by viruses belonging to the Flaviviridae family, such as HCV, comprising administering an Ara-C homologue to the host.
Refolded Recombinant Β-Secretase Crystals And Methods For Preparing And Using The Same
Brian M. Beyer - Matawan NJ, US Bruce A. Malcolm - Paoli PA, US Corey O. Strickland - Martinsville NJ, US Wenyan Wang - Edison NJ, US Eileen Wilson - Raritan NJ, US
Assignee:
Schering Corp. - Kenilworth NJ
International Classification:
C12N 1/12
US Classification:
530380
Abstract:
The present application relates to methods for growing crystals of both the uncomplexed and complexed forms of β-secretase (BACE) polypeptide. The present application also relates to crystalline forms of uncomplexed BACE and the three-dimensional structure of BACE, as determined from the crystals. In addition, the present application relates to the use of crystalline forms of BACE to identify ligands, preferably inhibitors (antagonists), which bind to, and preferably inhibit the enzymatic activity of, BACE. Furthermore, the present application relates to nucleic acid sequences encoding BACE polypeptide, and methods for making BACE in greater quantity than prior methods, resulting in more effective crystallization.